Anti-Aging Drug Candidate Completes Phase 1
Juvenescence has completed its Phase 1 trial for a first-in-class PAI-1 inhibitor. The drug, which targets aging and fibrosis, demonstrated a favorable safety profile and will now advance to Phase 2 trials.
The drug candidate, known as MDI-2517, is a small molecule designed to inhibit plasminogen activator inhibitor-1 (PAI-1). Elevated levels of PAI-1 are linked to a variety of age-related conditions, including fibrosis, which is the harmful scarring of organs, and blood clotting disorders. In fact, some human genetic studies suggest that people with naturally lower PAI-1 activity tend to live about 10 years longer. Juvenescence's advancement of this drug was bolstered by its collaboration with MDI Therapeutics, a company specializing in serpins, the class of proteins to which PAI-1 belongs. In March 2022, Juvenescence invested up to $9 million in MDI to help move their lead PAI-1 inhibitor through the initial clinical trial phase. The successful Phase 1 trial, which began in June 2024, was a randomized, double-blind, placebo-controlled study involving up to 48 healthy participants. Its main goal was to assess the drug's safety, tolerability, and how it's processed by the body. The positive results from this phase mean the company now has the safety data required to move forward. The upcoming Phase 2 trial will shift focus from safety to efficacy. This next stage will involve a larger group of participants who actually have the targeted conditions, such as metabolic and fibrotic diseases. Researchers will aim to determine if the drug has a beneficial effect on the disease and establish the optimal dosage. This phase can last from several months to a couple of years. Behind this clinical milestone are various scientific career paths. A computational biologist, for example, would have been involved in the early "AI-enabled" discovery process. Their work involves using computer models to analyze massive biological datasets, identifying potential drug targets like PAI-1, and even simulating how a molecule like MDI-2517 might interact with the protein before it's ever created in a lab. On the patient-facing side, Clinical Research Associates (CRAs) were essential during the Phase 1 trial. A CRA's day involves traveling to trial sites, meticulously reviewing patient data and records to ensure accuracy, and verifying that the strict trial protocols are being followed. They act as the key link between the drug sponsor, like Juvenescence, and the doctors and nurses conducting the study.
